James S Minnion
Overview
Explore the profile of James S Minnion including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davies I, Adriaenssens A, Scott W, Carling D, Murphy K, Minnion J, et al.
Mol Metab
. 2025 Jan;
92:102094.
PMID: 39788289
Objectives: There is renewed interest in targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) for treatment of obesity and type 2 diabetes. G-protein coupled receptor desensitisation is suggested to reduce the...
2.
Lopes T, Hope D, Ramos-Pittol J, Curtis A, Shrewsbury J, Davies I, et al.
Mol Metab
. 2024 Sep;
89:102024.
PMID: 39236784
Objective: Glucagon has long been proposed as a component of multi-agonist obesity therapeutics due to its ability to induce energy expenditure and cause weight loss. However, chronic glucagon-receptor agonism has...
3.
Hope D, Hinds C, Lopes T, Vincent M, Shrewsbury J, Yu A, et al.
Cell Rep Med
. 2022 Nov;
3(11):100810.
PMID: 36384093
Glucagon analogs show promise as components of next-generation, multi-target, anti-obesity therapeutics. The biology of chronic glucagon treatment, in particular, its ability to induce energy expenditure and weight loss, remains poorly...
4.
Hinds C, Owen B, Hope D, Pickford P, Jones B, Tan T, et al.
Sci Rep
. 2021 Nov;
11(1):22577.
PMID: 34799628
Glucagon receptor agonists show promise as components of next generation metabolic syndrome pharmacotherapies. However, the biology of glucagon action is complex, controversial, and likely context dependent. As such, a better...
5.
Ling Y, Galusca B, Martin F, Bartova S, Carayol J, Moco S, et al.
J Cachexia Sarcopenia Muscle
. 2020 Apr;
11(5):1187-1199.
PMID: 32274897
Background: Constitutional thinness (CT), a non-malnourished underweight state with no eating disorders, is characterized by weight gain resistance to high fat diet. Data issued from muscle biopsies suggested blunted anabolic...
6.
Germain N, Cuenco J, Ling Y, Minnion J, Bageacu S, Grouselle D, et al.
Am J Physiol Gastrointest Liver Physiol
. 2018 Dec;
316(3):G366-G371.
PMID: 30576216
Activation of ghrelin is controlled by the enzyme ghrelin- O-acyl transferase (GOAT). In humans, localization of this acylation is poorly understood. The aim of this study is to explore GOAT...
7.
Estour B, Marouani N, Sigaud T, Lang F, Fakra E, Ling Y, et al.
Psychoneuroendocrinology
. 2017 Jul;
84:94-100.
PMID: 28692876
Introduction: Constitutional thinness (CT) is an underweight state characterized by normal menstruations and no change in feeding behaviour. Thinness is the only resemblance between Anorexia Nervosa (AN) and CT. Removal...
8.
Price S, Minnion J, Bloom S
Curr Ther Res Clin Exp
. 2016 Feb;
77:111-5.
PMID: 26843896
Aims: To investigate the effect of Glu-3 OXM-like analogues on food intake and bodyweight in male rats. Background: Oxyntomodulin (OXM) is a natural agonist at both the glucagon receptor (GCGr)...
9.
Akalestou E, Christakis I, Solomou A, Minnion J, Rutter G, Bloom S
Pancreas
. 2016 Jan;
45(7):967-73.
PMID: 26731187
Objectives: Reports have suggested a link between treatment with glucagon-like peptide 1 (GLP-1) analogs and an increased risk of pancreatitis. Oxyntomodulin, a dual agonist of both GLP-1 and glucagon receptors,...
10.
Price S, Minnion J, Bloom S
Peptides
. 2015 Oct;
73:95-100.
PMID: 26431789
Oxyntomodulin analogues offer a novel treatment for obesity. However during analogue screening in a rat model increased food intake was consistently observed. To further investigate this finding, a series of...